Giant Biogene Holding Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Quarter	H1 2026	H2 2025	H1 2025	H2 2024	H1 2024	H2 2023	H1 2023	H2 2022	H1 2022	H1 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Jun '22 Jun 30, 2022	May '21 May 31, 2021
Revenue	2,918	2,406	3,113	2,998	2,540	1,918	1,606	1,380	984.89	520.6
Revenue Growth (YoY)	-6.26%	-19.76%	22.53%	56.29%	58.21%	39.06%	63.03%	-	89.19%	-
Cost of Revenue	599.28	514.85	570.32	544.71	447.19	322.3	254.7	222.57	146.64	72.98
Gross Profit	2,318	1,891	2,542	2,454	2,093	1,596	1,351	1,157	838.25	447.62
Selling, General & Admin	1,347	1,083	1,141	1,201	957.67	658.5	602.66	503.14	314.3	118.45
Research & Development	45.52	47.62	41.18	57.8	48.7	40.96	34.01	25.23	18.82	8.06
Other Operating Expenses	-17.02	-	-	-	-	-	-	-	-	-
Operating Expenses	1,375	1,130	1,182	1,259	1,007	699.09	636.34	529.13	332.97	126.35
Operating Income	943.19	760.71	1,360	1,195	1,086	897.05	714.66	627.85	505.29	321.27
Interest Expense	-0.18	-0.18	-0.12	-0.19	-0.05	-0.06	-0.06	-0.02	-	-
Interest & Investment Income	116.8	104.28	63.4	72.36	38.99	23.73	23.76	6.5	6.66	5.04
Earnings From Equity Investments	9.83	9.5	-	-3.6	-	-	-	-	-	-
Currency Exchange Gain (Loss)	-	-14.97	-	-3.59	-	1.09	-	-12.58	-1.87	-
Other Non Operating Income (Expenses)	25.32	-3.11	20.8	-1.52	29.87	33.55	22.03	45.97	8.23	5.47
EBT Excluding Unusual Items	1,095	856.22	1,444	1,259	1,155	955.37	760.39	667.72	518.31	331.79
Gain (Loss) on Sale of Investments	-	49.93	-	43.27	-	14.14	15.19	-3.07	-5.21	10.23
Gain (Loss) on Sale of Assets	-	-	-	0.67	-	-	-	-	-	-
Pretax Income	1,095	906.16	1,444	1,303	1,155	969.51	775.58	664.66	513.09	342.02
Income Tax Expense	155.43	173.94	261.7	221.39	174.64	187.33	109.56	100.31	75.85	52.5
Earnings From Continuing Operations	939.53	732.22	1,182	1,081	980.55	782.18	666.02	564.34	437.24	289.52
Minority Interest in Earnings	0.19	0.54	-0.36	-1.99	2.61	2.63	0.92	0.44	-	-
Net Income	939.71	732.75	1,182	1,079	983.16	784.81	666.94	564.78	437.24	289.52
Preferred Dividends & Other Adjustments	-	-	-	-	-	-	-	179.83	126.2	-
Net Income to Common	939.71	732.75	1,182	1,079	983.16	784.81	666.94	384.96	311.04	289.52
Net Income Growth (YoY)	-20.50%	-32.10%	20.23%	37.51%	47.41%	103.87%	114.42%	-	7.44%	-
Shares Outstanding (Basic)	1,050	1,059	1,035	975	988	958	995	721	685	1,000
Shares Outstanding (Diluted)	1,056	1,070	1,049	990	1,013	960	1,006	987	1,055	1,000
Shares Change (YoY)	0.60%	7.98%	3.58%	3.20%	0.72%	-2.76%	-4.71%	-	5.54%	-
EPS (Basic)	0.89	0.69	1.14	1.11	0.99	0.82	0.67	0.53	0.45	0.29
EPS (Diluted)	0.89	0.68	1.13	1.09	0.97	0.82	0.66	0.53	0.41	0.29
EPS Growth (YoY)	-21.24%	-37.30%	16.50%	33.16%	46.97%	53.49%	59.31%	-	43.10%	-

Additional Metrics

Fiscal Quarter	H1 2026	H2 2025	H1 2025	H2 2024	H1 2024	H2 2023	H1 2023	H2 2022	H1 2022	H1 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Jun '22 Jun 30, 2022	May '21 May 31, 2021
Free Cash Flow	-	915.68	436.84	1,037	757.38	915.2	505.93	510.17	268.8	176.62
Free Cash Flow Per Share	-	0.86	0.42	1.05	0.75	0.95	0.50	0.52	0.26	0.18
Operating Margin	32.33%	31.62%	43.70%	39.86%	42.76%	46.76%	44.51%	45.51%	51.30%	61.71%
Profit Margin	32.21%	30.46%	37.98%	35.99%	38.70%	40.91%	41.54%	27.90%	31.58%	55.61%
Free Cash Flow Margin	-	38.06%	14.03%	34.59%	29.81%	47.70%	31.51%	36.98%	27.29%	33.93%
EBITDA	980.27	800.26	1,395	1,219	1,106	912.78	730.55	640.38	518.29	330.58
D&A For EBITDA	37.08	39.55	34.61	24.29	19.63	15.73	15.89	12.52	13.01	9.31
EBIT	943.19	760.71	1,360	1,195	1,086	897.05	714.66	627.85	505.29	321.27